NCT05856643

Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Ovarian Epithelial Carcinoma

Recruiting now EARLY_PHASE1 Last updated 13 August 2024

What this trial tests

EARLY_PHASE1 trial testing SZ011 CAR-NK in Ovarian Epithelial Carcinoma in 12 participants. Currently enrolling.

Timeline

13 August 2024

Primary endpoint
1 June 2025

30 December 2025

Quick facts

Lead sponsor	Shantou University Medical College
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	13 August 2024
Primary completion	1 June 2025
Estimated completion	30 December 2025
Sites	1 location across China

Drugs / interventions tested

• SZ011 CAR-NK — full drug profile →

Conditions studied

• Ovarian Epithelial Carcinoma — all drugs for Ovarian Epithelial Carcinoma →

Sponsor

Shantou University Medical College

Who can join

Adults 18 to 80, female only, with Ovarian Epithelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was a single-center, open-label, investigator-initiated clinical trial (IIT) to observe and investigate the clinical safety and efficacy of SZ011 in the treatment of ovarian epithelial carcinoma

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Forks in the road for CAR T and CAR NK cell cancer therapies.
   Dagher OK, Posey AD. · · 2023 · cited 126× · PMID 38012406 · DOI 10.1038/s41590-023-01659-y
2. Development of NK cell-based cancer immunotherapies through receptor engineering.
   Page A, Chuvin N, Valladeau-Guilemond J, Depil S. · · 2024 · cited 123× · PMID 38443448 · DOI 10.1038/s41423-024-01145-x
3. Breakthrough of solid tumor treatment: CAR-NK immunotherapy.
   Wang W, Liu Y, He Z, Li L, et al · · 2024 · cited 113× · PMID 38245520 · DOI 10.1038/s41420-024-01815-9
4. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.
   Chen S, Zhu H, Jounaidi Y. · · 2024 · cited 106× · PMID 39511139 · DOI 10.1038/s41392-024-02005-w
5. The clinical landscape of CAR NK cells.
   Jørgensen LV, Christensen EB, Barnkob MB, Barington T. · · 2025 · cited 61× · PMID 40149002 · DOI 10.1186/s40164-025-00633-8
6. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside.
   Zhang B, Yang M, Zhang W, Liu N, et al · · 2024 · cited 50× · PMID 38221520 · DOI 10.1038/s41419-024-06438-7
7. The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.
   Yao P, Liu YG, Huang G, Hao L, et al · · 2024 · cited 19× · PMID 39633491 · DOI 10.1186/s40164-024-00583-7
8. Natural killer cell-based cancer immunotherapy: from basics to clinical trials.
   Shi Y, Hao D, Qian H, Tao Z. · · 2024 · cited 17× · PMID 39415291 · DOI 10.1186/s40164-024-00561-z